SD Biosensor Targets KRW 1.2 Trillion in Consolidated Revenue by 2029

• SD Biosensor targets 2029 consolidated revenue of KRW 1.2 trillion with a 13% operating margin under its corporate value enhancement plan.
• Other targets include EBITDA of KRW 250 billion and a price-to-book ratio of 1.0 times.
• Molecular diagnostics expansion will focus on M10 installations, broader testing menus and European IVDR compliance and US FDA clearance to grow recurring reagent sales.
• Growth initiatives include expanding international procurement sales for rapid diagnostics and entering global automated immunodiagnostics markets with STANDARD i.
• Shareholder returns will include continued dividends and treasury share cancellations during 2026–2028, with interim dividends planned if earnings improve.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SD Biosensor Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261028800767), on October 28, 2026, and is solely responsible for the information contained therein.